Skip to the content
ClearNote Health logologo darklogo light
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
Search
ClearNote Health logo
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
ClearNote Health logo
  • Our Story
    • About Us
    • Leadership Team
    • FAQs
    • Careers
  • Our Approach
    • Epigenomics Platform
    • Clinical Trials
    • Publications
  • Our Products
    • Biopharma
    • Pancreatic Cancer
    • Ovarian Cancer
  • Our News
  • Contact Us
  • Order Test
Home2023May
Press Release

Study Validating ClearNote Health’s Avantect Pancreatic Cancer Detection Test Published in the Journal Clinical Gastroenterology and Hepatology

ClearNote Health
May 8, 2023
Event

Society for Laboratory Automation and Screening | May 2023

cnhnewcorpdev
May 1, 2023

ClearNote Health Announces Leadership Transition

ClearNote Health
July 9, 2026

Meet Us at ASCO 2026

ClearNote Health
May 28, 2026

Follow us
ClearNote Health logo

Empowering early cancer detection.

Order Test
Company
  • About Us
  • Leadership Team
  • Our News
  • Careers
  • Contact Us
Solutions
  • Avantect Pancreatic Cancer Test
  • Avantect Ovarian Cancer Test
  • Virtuoso Epigenomics Platform
Stay Informed

Get the latest research and announcements from ClearNote Health. Follow us:

Important information: 
The Virtuoso platform is for research use only. Not for use in diagnostic procedures. The Avantect Pancreatic and Ovarian Cancers Tests are early detection tests. The tests do not establish a diagnosis of pancreatic cancer or ovarian cancer, respectively, and results should be considered in the context of other clinical criteria.

Cancer statistics quoted on this website are taken from the CDC and SEER websites, 2025 data.

©2026 ClearNote Health, All Rights Reserved.

Avantect and Virtuoso are trademarks of ClearNote Health. Other trademarks are the property of their respective owners.

  • Privacy Policy
  • Terms of Use
  • Billing rights & protections
  • Cookie Preferences